ABSTRACT
RÉSUMÉ CONTEXTE: Avec l'introduction du traitement antirétroviral hautement actif (HAART) l'évolution du VIH / sida est passé d'un tueur à une maladie infectieuse chronique traitable. Toutefois HAART est associée à certains troubles métaboliques dont certaines sont en train d'être vu chez les personnes vivant avec le VIH / sida (PVVIH) d'accès aux soins de notre centre. OBJECTIF: Pour déterminer la prévalence et la structure de la dyslipidémie et dysglycaemia nigériane entre le VIH / sida sur le traitement HAART. MÉTHODES: les PVVIH qui ont été régulièrement sous ARV pendant au moins trois mois et a pré-traitement CD4 + count, le jeûne de lipides et de glucose profils ont été regroupés en deux régimes de traitement: inhibiteur de protéase (IP) ou non-nucléosidiques de la transcriptase inverse inhibiteur (INNTI). Pré et post-exposition métaboliques et non-métaboliques variables ont été comparés pour chaque régime, ainsi que dans le régime comparaison des différences entre post-exposition métaboliques variables.

RÉSULTATS: Trois cent vingt-sept patients, [les hommes = 134 (41%), les femmes = 193 (59%)] a rencontré l'étude des critères dans les deux groupes: PI = 94 (29%) et INNTI = 233 (71% ). Le prétraitement des changements métaboliques dans les deux groupes (c. INNTI IP) sont faibles HDL-C, 29 (31%) vs.77 (33%), suivie par l'hypertriglycéridémie, 16 (17%) vs.38 (16%) et l'hypercholestérolémie , 6 (6%) vs.10 (4%)
.
ORIGINAL ARTICLE
INTRODUCTION
The clinical benefit of Antiretroviral (ARV) drugs in ameliorating symptoms of AIDS and improving survival of HIV/ AIDS patients has been documented in our centre along with some short term side effects of these drugs. 1 Although we monitored only the CD4 + lymphocytes rise in response to Highly Active Antiretroviral Therapy (HAART), our experience of improved quality of life of PLWHA was similar to that of those 2,3 that monitored both viral load decline and rising levels of CD4 + cells count in response to HAART. Nigerian. Persons Living with HIV/AIDS (PLWHA) are now leaving long enough for some of the longer term side effects of ARV to manifest in them. The medical literature is full of reports of some of these side effects; such as lipodystrophy 4 , dyslipidaemia, 5 IFG and frank diabetes mellitus 6 and lately increasing risks of cardiovascular diseases. 7 We have started to observe some of these metabolic derangements especially that of lipid profiles and blood sugar in some PLWHA on HAART during their followup assessment. This was what informed our aim of determining the prevalence and pattern of dyslipidaemia and glucose disorders amongst PLWHA accessing ARV drugs from the University of Ilorin teaching hospital; a tertiary care centre in Nigeria.
SUBJECTS, MATERIALS AND METHODS
The study site was the Infectious Diseases clinics of the Department of Medicine at the University of Ilorin Teaching Hospital, Ilorin. The subjects were all the PLWHA who were on ARV drugs since commencement of HAART programme in 2002. However, for the purpose of this study the inclusion criteria were records of pretreatment CD4 + count, lipid profile: [total cholesterol (T-C), low density lipoprotein cholesterol (LDL-C), high density lipoprotein cholesterol (HDL-C), triglyceride] and fasting plasma glucose (FPG) and at least 12 weeks of regular ARV therapy. Patients who satisfied these criteria were placed in either of two treatment groups; Pi based: ritonavir or indinavir {RTV or IDV} + stavudine {D4T} + lamivudine {3TC} and NNRTI based; nevirapine or efavirenz {NVP or EFV} + D4T + 3TC ARV therapy.
All ARV drugs were accessed from the national ARV programme and therefore what determined ARV drugs combination of a patient were partly drugs availability and toxicities and intolerance to any of the drugs. Choice of suitable alternatives was sometimes also limited by availability. All the patients received 2 NRTI (D4T + 3TC) as the backbone of the 2 regimens.
Patients that satisfied the study criteria were informed about the proposed study and their consent was obtained. PLWHA who had co-morbidities like DM, chronic liver or renal diseases or medications that could influence serum lipids were excluded. Thereafter their age, sex, weight at the time of commencement of ARV drugs as well as the duration and type of the ARV drug combinations were obtained from their respective hospital files. On the morning of follow-up clinics, each patient had his/her venous blood drawn for serum lipids and glucose measurement after a 12-hour overnight fast. Fasting serum lipids and lipoproteins were assayed by enzymatic technique (QCA kit, Spain). 8 Serum HDL-C was also determined by enzymatic method after precipitation of low density and very low density lipoproteins with dextran sulfate MgCl2 (QCA kit, Spain). 9 FPG was determined by the glucose oxidase method. 10 Disordered levels were defined according to the WHO guidelines 11 as T-C (>5.2mmol/l), triglyceride (1.8mmol/l), HDL-C (<0.8mmol/l), LDL-C (>4.65mmol/ l) and elevated FPG was as defined by the expert committee on the diagnosis and classification of DM 6 as FPG > 6.1 mmol/L but <7.0 mmol/L was defined as impaired fasting glycaemia (IFG) and FPG, >7.0 mmol/L was diagnostic of DM. A minimum of 12 weeks of regular ARV therapy was chosen because this was the 301 
changes and a predictor ARV regimen) was estimated with a 95% confident limit. Possible gender association with metabolic variables was also determined by cross tabulation test. P-value value of less 0.05 was upheld as statistically significant.
RESULTS
Three hundred and twenty-seven patients; [males = 134 (41%) and females = 193, (59%)] met the study inclusion criteria in the two groups: Pi= 94(29%) and NNRTI= 233(71%), ( Table 1 ). The mean age in both groups; Pi vs. NNRTI was about the same 34.5 ± 8.3 vs. 31.3 ± 5.7years, p-= 0.96, as was the preexposure mean weight; 45.4 ± 7.7 vs. 48.8 ± 7.9kg and CD4 + cell count; 126.4 ± 17.6 vs.122.4 ± 17.8cells/ul, Table 2 . The average lengths of exposure to either of these two regimens were 77.2 ± 22.3 weeks and 108.5 ± 38.6 weeks respectively. The commonest pre ARV exposure metabolic abnormality in both Pi vs. NRTI groups was low HDL-C;29(31%) vs.77(33%),followed by hypertriglyceridaemia;16(17%) vs. 38(16%) and hypercholesterolaemia; 6(6%) vs.10(4%). IFG was seen in both Pi and NNRTI groups; 5(5%) vs. 8(4%) of the cases.
Post ARV exposure (Pi vs. NNRTI) mean weight improved by 23.4kg 5 (5) 13 (14) 8 (4) 43 ( researcher 4 have attributed pre exposure dyslipidaemia to the enhanced lipogenesis and impaired postprandial triglyceride clearance that often result from increased generation of tumor necrosis factor-á (TNFá) and interferon-ã (IFNã) cytokines at an advanced stage of HIV/AIDS spectrum.
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The post exposure metabolic abnormalities in order of prevalence were hypertriglyceridaemia, hypercholesterolaemia and IFG as well as DM. These occurred in both Pi and NNRTI treatment groups to a varying degree, the Pi group induced more of hypertryglyceridaemia, hypercholesterolaemia and LDL-C while NNRTI induced more of high HDL-C and IFG. In fact patients that received Pibased therapy had a threefold increased risk of developing hypertriglyceridaemia and about two and a halve time higher risk of developing hypercholesterolaemia over the NNRTI recipients. These risks were evident in the percentage distribution of cases of dyslipidaemia that met the National Cholesterol Education Program guidelines intervention criteria 13 where 79% and 51% of all Pi recipients developed hypertriglyceridaemia and hypercholesterolaemia compared to 54% and 31% on NNRTI therapy.
Dyslipidaemia was commoner in females while dysglycaemia occurred more in males. However, because of the small number of diabetic cases, seven (3%) in all, it is difficult to rationalize on this observation. Furthermore, this relative high rate of DM in the NNRTI group was at variance with widely cited studies 14, 15 that reported high level of dysglycaemia from Pi based therapy. This was ascribed to Pi induced insulin resistance. Our experience, however, was similar to some other reports 16, 17 that had observed more cases of dysglycaemia from NNRTI based therapy. Reasons for this may have to be further investigated. The Pi-associated dyslipidaemia on the other hand could partly be due to the use of plain ritonavir and indinavir which are known to be prone to inducing dyslipidaemia 18, 19 . These two unboosted drugs are the commonly prescribed Pi for our patients because the boosted varieties are not readily available on the national programme. Stavudine on its own could have contributed to the
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Serum Lipids and Glucose Abnormalities 303 There was a gender difference in the occurrence of these post exposure metabolic changes being commoner in females than males, Table 6 . Hypertriglyceridaemia remained the commonest abnormality followed by hypercholesterolaemia and elevated LDL-C. These occurred in both Pi-and NNRTIbased therapies but, more frequent in ARV drug regimens containing EFV, RTV and IDV in that descending order. DM occurred in seven (3%) cases, six males and a female; all were in NNRTI group; five patients in EFV containing regimen and one in NVP containing NNRTI.
DISCUSSION
Majority of the patients seen in this study had advanced HIV/AIDS and presented late for care as shown by their low mean pretreatment weight and CD4 + cells count. Fear of stigmatization which we have reported in one of our series could be responsible for this 12 . Both Pi and NNRTI regimens prevented progression of diseases in their recipients as evidenced by improvement in their weight and CD4 + cell counts after ARV exposure. This has indirectly confirmed the effectiveness of Pi therapy in our patients as that of NNRTI had earlier been reported. 1 Possibly because of the severity of the disease, a number of lipid and glycaemic abnormalities were observed at baseline; these included in order of decreasing frequency low HDL-C, hypertriglyceridaemia, hypercholesterolaemia, and IFG. All these except low HDL-C were seen in patients with very severe disease, their CD4 + count ranged between 3-48cells/ul. It might therefore mean that very low CD4 + count was a predictor of dyslipidaemia in ARV naïve AIDS patients. Some 
